Isabella Ciccone, MPH

Findings from a new study showed that over 90% of counties in the United States lacked a UCNS-certified headache specialist, with access lowest in socioeconomically disadvantaged and rural areas.

Catch up on any of the neurology headlines you may have missed in August 2026, compiled into 1 place by the NeurologyLive® team.

Newly published longitudinal fMRI data revealed that presymptom Huntington gene carriers had striatal network shifts up to 20 years early, potentially sharpening targets for studies in the future.

A recently published multiple sclerosis study suggests disease-modifying therapy use may be associated with higher rates of human papillomavirus positivity, cervical abnormalities, and other gynecologic complications.

The randomized NATURE trial, presented as late-breaking science at ESC Congress 2026, showed that enVast-assisted thrombectomy reduced infarct size versus standard PCI in STEMI with large thrombus burden.

Lucy Morse, MD, a movement disorders specialist at Northwestern Medicine, discussed the push toward a biological definition for Parkinson disease, newly approved therapies, and why she believes referrals shouldn't wait.

Findings showed that remibrutinib outperformed teriflunomide in the REMODEL-1 and REMODEL-2 phase 3 trials among adults with relapsing MS, lowering relapse rates and MRI lesions with a favorable safety profile.

Hannah Kopinsky, MD, an MS specialist at Northwestern Medicine, discussed recent updates to multiple sclerosis diagnostic criteria, the shift toward early high-efficacy treatment, and the unmet needs that remain in progressive MS.

In recognition of SMA Awareness Month, NeurologyLive® spoke with neuromuscular experts about how multidisciplinary care is built, where coordination breaks down, and what changes as patients live longer.

In recognition of SMA Awareness Month, NeurologyLive® spoke with neuromuscular experts about how multidisciplinary care is built, where coordination breaks down, and what changes as patients live longer.

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.

In honor of SMA Awareness Month, held annually throughout August, get caught up on the latest news in spinal muscular atrophy from 2026, 5 headlines compiled in one place by the NeurologyLive® team.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 28, 2026.

In recognition of SMA Awareness Month, held annually throughout August, NeurologyLive® reviews the investigational agents currently moving through clinical development for spinal muscular atrophy.

The phase 3 clinical program for salanersen, an investigational intrathecally administered antisense oligonucleotide, will test the efficacy of the agent across infants, adolescents and adults living with SMA.

Nestor Galvez-Jimenez, MD, a neurologist at Baptist Health Miami Neuroscience Institute, discussed how advancements have changed the landscape of care for patients living with spinal muscular atrophy.

Regenxbio recently announced that the FDA placed RGX-121 on hold after spinal MRI abnormalities emerged in 5 participants with MPS II and does not expect a near-term BLA filing.

Dustin Gable, MD, PhD, a pediatric neuromuscular neurologist at Johns Hopkins Medicine, discussed why bulbar dysfunction remains an underrecognized burden among patients with spinal muscular atrophy.

Here's some of what is coming soon to NeurologyLive® this week.

The Stewart J. Greenebaum Endowed Professor in Stroke Neurology at University of Maryland discussed the unmet needs in secondary stroke prevention. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 21, 2026.

FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for adults 40 years and older with cognitive symptoms, offering fast amyloid and tau insight to guide diagnosis and trials in Alzheimer disease.

Nicholas Streicher, MD, MPH, an assistant professor of neurology at Georgetown University, discussed the training, handoff, and coding gaps that can leave adults with spinal muscular atrophy without follow-up care.

A recently published phase 2 trial showed that CBD/THC cannabis oil failed to ease chronic pain or nonmotor symptoms versus placebo among patients with Parkinson disease.

The chief of neurology at Nemours Children’s Health outlined the specialties that may be essential to comprehensive care for patients with spinal muscular atrophy. [WATCH TIME: 5 minutes]

Teva Pharmaceuticals' ecopipam receives priority review by the FDA, supported by studies showing sustained tic control among pediatric patients with Tourette syndrome.

Alexandra Bonner, MD, a pediatric neuromuscular neurologist at Cleveland Clinic, discussed why real-time communication between specialists is the hardest part of multidisciplinary care for patients with spinal muscular atrophy.

Alexandra Bonner, MD, a pediatric neuromuscular neurologist at Cleveland Clinic, discussed which specialties are essential to a spinal muscular atrophy care team and why anticipating future needs has become central to the work.

W. Bryan Burnette, MD, chief of neurology at Nemours Children’s Health in Jacksonville, Florida, discussed why access to adult subspecialty care has become one of the largest remaining challenges in spinal muscular atrophy.